Navigation Links
Boston Scientific to Participate in Merrill Lynch Conference
Date:1/30/2008

NATICK, Mass., Jan. 30 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference, which is being held February 5-7 in New York City.

Paul LaViolette, Chief Operating Officer, will make a 40-minute presentation on Wednesday, February 6, beginning at approximately 10:20 a.m. E.T. Sam Leno, Executive Vice President and Chief Financial Officer will join Mr. LaViolette in a question and answer session.

A live webcast of Mr. LaViolette's remarks and the question and answer session will be available to all interested parties at Boston Scientific's website at http://www.bostonscientific.com. Please visit the website for details on how to access the webcast. To ensure a timely connection to the webcast it is recommended that users register at least 15 minutes before the webcast begins.

This webcast is being hosted by Merrill Lynch. The replay will be archived and available in the Investor Relations site at http://www.bostonscientific.com.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Dan Brennan

508-
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
2. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
3. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
4. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
5. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
6. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
7. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
8. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
9. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Genzyme Begins Major Expansion of Boston Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), ... cancer therapies in new orphan drug indications, today announced ... been added as a clinical trial site for the ... with refractory glioblastoma multiforme (GBM), the most common and ...
(Date:4/16/2015)... 16, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... non-toxic DCVax® personalized immune therapies for cancer, announced ... Loncar Cancer Immunotherapy Index (LCINDX), a professional index ... immunotherapy field within the biotechnology space.  ... 25 companies" in the immunotherapy space, including 6 ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Modality ... management systems for highly regulated industries, is pleased ... name a monthly columnist for Cold Chain IQ ... http://www.coldchainiq.com ). His column titled, Global Cold Chain ... information for today’s life sciences, pharmaceutical and healthcare ...
(Date:4/15/2015)... April 16, 2015 Immunocore ... drugs to treat cancer and other diseases, and ... of AstraZeneca, today announced that they have entered ... terms of the agreement, Immunocore will conduct a ... inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, ...
Breaking Biology Technology:DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 2Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 4Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 5Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 6
... DNDN ) today announced the Medicare Evidence ... of labeled and unlabeled use of PROVENGE® (sipuleucel-T) treatment ... This panel was convened as a part of the ... Centers for Medicare and Medicaid Services (CMS).   ...
... ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) ... CTI,s Pixuvri (pixantrone dimaleate) Pediatric Investigation Plan ("PIP") for ... children between the ages of six months and 18 ... EMA adopted an opinion agreeing to the PIP and ...
Cached Biology Technology:Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 2Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 2Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 4Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 5Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 6Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 7Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 8Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 9Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 10European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri 2European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri 3
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/26/2015)... TORONTO , March 26, 2015 ... premier family, social, recreation and athletic club, today announced ... designed to allow freedom of movement for members and ... "Following a comprehensive process, we selected FST,s IMID ... sophistication and convenience for our members and staff, in ...
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) have developed a ... fight against a disease for which no vaccines are yet ... that this vaccination technique may be effective against HCV. The ... , The team, funded by the Canadian Institutes of ...
... and the Department of Horticulture in the College ... have developed a new procedure for the efficient ... of strawberry. The scientists have used Agrobacterium tumefaciens, ... woodland or alpine strawberry Fragaria vesca. , ...
... of molecule which they believe could ultimately lead to ... modified tobacco. Writing in Plant Biotechnology Journal, Dr Patricia ... along with researchers at the University of Warwick say ... far frustrated attempts to turn plants into economically viable ...
Cached Biology News:U of S researchers develop new vaccine candidate against hepatitis C 2Strawberries by design 2Do plants have the potential to vaccinate against HIV? 2
... Agencourt offers pre-validated ... over 1500 amplicons within ... serine/threonin kinases, and more ... These assays were ...
... 384-Well Microarray plates are ideal for use as ... liquid handling applications (down to 5µl). These plates ... well design. Features 384 ... available 70µl well volume (cylindrical well), 55µl ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
...
Biology Products: